RareWays is a research directory. It helps you understand the science. It is not medical advice. Always discuss your care options with your healthcare team.
Coverage: 2020-01-01 onwards, with up to 300 results per query from PubMed and Europe PMC and separate limits on other sources. This is a selected index, not a complete literature search.
Updates are delayed or unverified. Check original sources for the latest information.
Your saved research and appointment questionsView recorded trial and retraction changes
Alpha-Thalassaemia: Research Summary
Printed from RareWays (rareways.org)
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
Alpha-thalassaemia: from regional burden to global priority.
Amid Ali et al., The Lancet regional health. Southeast Asia (1 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42787732/
- 2.
Placental iron deposition and altered FOXP3/PGF expression in pregnancies complicated by HbH disease.
Yang Dongmei et al., Placenta (14 September 2026)
https://pubmed.ncbi.nlm.nih.gov/42800417/
- 3.
[Alpha-thalassemia with Hb G-Philadelphia incidentally discovered during HbA1c testing].
Kahouli Sophia et al., Annales de biologie clinique (27 August 2026)
https://pubmed.ncbi.nlm.nih.gov/42470431/
- 4.
AI-CADD-Guided Identification of Catechin as an Erythroferrone-Targeting Lead for Alpha-Thalassemia-Associated Iron Overload
Nouman Safdar Ali, Zenodo (CERN European Organization for Nuclear Research) (16 August 2026)
https://doi.org/10.5281/zenodo.21963136
- 5.
AI-CADD-Guided Identification of Catechin as an Erythroferrone-Targeting Lead for Alpha-Thalassemia-Associated Iron Overload
Nouman Safdar Ali, Zenodo (CERN European Organization for Nuclear Research) (16 August 2026)
https://doi.org/10.5281/zenodo.21963137
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Alpha-Thalassaemia
Alpha-Thalassaemia is an inherited blood disorder caused by mutations in the alpha-globin genes, resulting in reduced or absent production of haemoglobin alpha chains. It has high prevalence in Southeast Asian and Mediterranean communities in Australia. Severity ranges from silent carrier status to severe haemolytic anaemia (HbH disease) and the life-threatening Haemoglobin Barts hydrops fetalis.
This overview is general information, not an individual medical assessment. Research is selected automatically and may include mismatches. How we select and explain research.
Most Recent Research
Common Questions
What is Alpha-Thalassaemia?
Alpha-Thalassaemia is an inherited blood disorder caused by mutations in the alpha-globin genes, resulting in reduced or absent production of haemoglobin alpha chains. It has high prevalence in Southeast Asian and Mediterranean communities in Australia. Severity ranges from silent carrier status to severe haemolytic anaemia (HbH disease) and the life-threatening Haemoglobin Barts hydrops fetalis.
How many clinical trials are available for Alpha-Thalassaemia?
RareWays currently indexes 2 clinical trials for Alpha-Thalassaemia, of which 1 is actively recruiting. These counts cover indexed trials across countries, not just your country. An Australian site does not necessarily mean that site is recruiting. Check locations, eligibility and current availability with the study team.
Where does the research data for Alpha-Thalassaemia come from?
RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is refreshed automatically every day. All articles and trials link directly to their original sources.
Get research updates
Monthly email when new findings are published for Alpha-Thalassaemia.
Your email and selected disease are stored for these updates. Unsubscribe any time. Privacy and deletion.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.